Adaptive Biotechnologies is trading at $28.41, up +6.36% after hours, following Q3 revenue of $83.9 million that topped the cited analyst estimate and company-wide profitability ahead of schedule. - The regular-session close was $26.71. - clonoSEQ test volumes rose 46%; total revenue declined 11% year over year, partly due to milestone-payment timing. - Earnings were released after the close, making them the clear company-specific catalyst.